Answers are grounded in this paper and cite their sources.
The unexpectedly high efficacy of cyclosporine in treating psoriasis was first observed in a patient with rheumatoid arthritis, 1 prompting physicians and scientists to hypothesize that T-cells play a central role in the disease's pathogenesis.Cyclosporine was subsequently approved for psoriasis vulgaris, demonstrating remarkable efficacy.2 This breakthrough spurred the development of T-cell-targeted therapies, including biologics, utilizing various modern approaches.The first biologic to target T-cell function was the anti-CD2 antibody alefacept.Alefacept inhibits memory effector T-cell activation by blocking the interaction between the adhesion molecule CD2 on T-cells and LFA-3 on antigenpresenting cells (APCs).Clinical trials demonstrated a PASI 50 rate of approximately 40% at the primary endpoint (12 weeks), compared to a placebo response of about 15%. 3 Another target, CTLA4, is a T-cell surface molecule that interacts with the co-stimulatory molecule CD80/86 on APCs, a critical step for T-cell activation.Blocking this interaction with CTLA4-Ig (abatacept) proved effective for rheumatoid arthritis and psoriatic arthritis 4 but showed minimal impact on the skin symptoms of psoriasis.5 CD11a, aRecent landscape in psoriasis
No takes yet. Share an insight, caveat, or question.
Shinichi Imafuku (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: